Logo image of ANVS

ANNOVIS BIO (ANVS) Stock Fundamental Analysis

NYSE:ANVS - New York Stock Exchange, Inc. - US03615A1088 - Common Stock - Currency: USD

2.94  +0.14 (+5%)

After market: 2.82 -0.12 (-4.08%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ANVS. ANVS was compared to 559 industry peers in the Biotechnology industry. While ANVS has a great health rating, there are worries on its profitability. ANVS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ANVS has reported negative net income.
In the past year ANVS has reported a negative cash flow from operations.
In the past 5 years ANVS always reported negative net income.
In the past 5 years ANVS always reported negative operating cash flow.
ANVS Yearly Net Income VS EBIT VS OCF VS FCFANVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

ANVS's Return On Assets of -108.69% is on the low side compared to the rest of the industry. ANVS is outperformed by 79.07% of its industry peers.
ANVS has a Return On Equity of -120.81%. This is comparable to the rest of the industry: ANVS outperforms 41.86% of its industry peers.
Industry RankSector Rank
ROA -108.69%
ROE -120.81%
ROIC N/A
ROA(3y)-265.83%
ROA(5y)-179.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ANVS Yearly ROA, ROE, ROICANVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

ANVS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANVS Yearly Profit, Operating, Gross MarginsANVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, ANVS has more shares outstanding
The number of shares outstanding for ANVS has been increased compared to 5 years ago.
There is no outstanding debt for ANVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ANVS Yearly Shares OutstandingANVS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
ANVS Yearly Total Debt VS Total AssetsANVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

An Altman-Z score of 2.83 indicates that ANVS is not a great score, but indicates only limited risk for bankruptcy at the moment.
ANVS's Altman-Z score of 2.83 is fine compared to the rest of the industry. ANVS outperforms 73.17% of its industry peers.
There is no outstanding debt for ANVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.83
ROIC/WACCN/A
WACCN/A
ANVS Yearly LT Debt VS Equity VS FCFANVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

ANVS has a Current Ratio of 10.68. This indicates that ANVS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 10.68, ANVS is in the better half of the industry, outperforming 79.96% of the companies in the same industry.
A Quick Ratio of 10.68 indicates that ANVS has no problem at all paying its short term obligations.
ANVS has a Quick ratio of 10.68. This is in the better half of the industry: ANVS outperforms 79.96% of its industry peers.
Industry RankSector Rank
Current Ratio 10.68
Quick Ratio 10.68
ANVS Yearly Current Assets VS Current LiabilitesANVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 59.52% over the past year.
EPS 1Y (TTM)59.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-220%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 15.00% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.16%
EPS Next 2Y5.14%
EPS Next 3Y-9.03%
EPS Next 5Y15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANVS Yearly Revenue VS EstimatesANVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ANVS Yearly EPS VS EstimatesANVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ANVS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANVS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANVS Price Earnings VS Forward Price EarningsANVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANVS Per share dataANVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A cheap valuation may be justified as ANVS's earnings are expected to decrease with -9.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.14%
EPS Next 3Y-9.03%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ANVS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANNOVIS BIO

NYSE:ANVS (6/12/2025, 8:04:00 PM)

After market: 2.82 -0.12 (-4.08%)

2.94

+0.14 (+5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-12 2025-08-12/bmo
Inst Owners13.3%
Inst Owner Change29.88%
Ins Owners14.4%
Ins Owner Change1.88%
Market Cap57.30M
Analysts81.67
Price Target29.99 (920.07%)
Short Float %11.73%
Short Ratio4.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.79%
Min EPS beat(2)-27.55%
Max EPS beat(2)11.97%
EPS beat(4)2
Avg EPS beat(4)-11.56%
Min EPS beat(4)-80.79%
Max EPS beat(4)50.15%
EPS beat(8)4
Avg EPS beat(8)-8.16%
EPS beat(12)6
Avg EPS beat(12)-25.22%
EPS beat(16)8
Avg EPS beat(16)-30.41%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.77%
PT rev (3m)-15.03%
EPS NQ rev (1m)11.02%
EPS NQ rev (3m)19.16%
EPS NY rev (1m)7.17%
EPS NY rev (3m)14.44%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.38
P/tB 2.38
EV/EBITDA N/A
EPS(TTM)-2.04
EYN/A
EPS(NY)-1.63
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS0
BVpS1.23
TBVpS1.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -108.69%
ROE -120.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-265.83%
ROA(5y)-179.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.68
Quick Ratio 10.68
Altman-Z 2.83
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-220%
EPS Next Y6.16%
EPS Next 2Y5.14%
EPS Next 3Y-9.03%
EPS Next 5Y15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y41.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-45.18%
EBIT Next 3Y-44.37%
EBIT Next 5Y22.26%
FCF growth 1Y11.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.42%
OCF growth 3YN/A
OCF growth 5YN/A